For example, studies have shown that anti-PD-L1 antibodies are associated with significantly lower rates of immune adverse events such as pneumonitis compared to anti-PD-1 in NSCLC patients across clinical trials. This evidence concerns the gene CD274 and non-small cell lung carcinoma.